Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.

Oncotarget - 2 Feb 2016

Iyer Swathi V, Parrales Alejandro, Begani Priya, Narkar Akshay, Adhikari Amit S, Martinez Luis A, Iwakuma Tomoo

Abstract excerpt

Many p53 hotspot mutants not only lose the transcriptional activity, but also show dominant-negative (DN) and oncogenic gain-of-function (GOF) activities. Increasing evidence indicates that knockdown of mutant p53 (mutp53) in cancer cells reduces their aggressive properties, suggesting that survival and proliferation of cancer cells are, at least partially, dependent on the presence of mutp53. However, these p53...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinogenesis
Share to Cell Adhesion

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Immunoenzyme Techniques

Share to Mutant Proteins

Share to Piperazines

Share to Real-Time Polymerase Chain Reaction

Share to RNA, Small Interfering

Source

Open in PubMed Open full text

Identifiers

PMID: 26700961
DOI: 10.18632/oncotarget.6634
PMCID: PMC4868694

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.PMID 26700961Read ↗

Cancer therapeutic targeting using mutant–p53-specific siRNAsSemantic proximity Read ↗

Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic TargetSemantic proximity Read ↗

Gain-of-function mutant p53 in cancer progression and therapySemantic proximity Read ↗

Drugs Targeting p53 Mutations with FDA Approval and in Clinical TrialsSemantic proximity Read ↗

Molecularly targeted therapies for p53-mutant cancers.Semantic proximity Read ↗

Mutant p53: it's not all one and the same.Semantic proximity Read ↗

Mutant p53 in cancer therapy—the barrier or the pathSemantic proximity Read ↗

Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression.Semantic proximity Read ↗

Gain of function of p53 cancer mutants in disrupting critical DNA damage response pathways.Semantic proximity Read ↗

Gain-of-function mutations in the tumor suppressor gene p53.Semantic proximity Read ↗

Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 MutationsSemantic proximity Read ↗

Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.